Relapsing-remitting multiple sclerosis
Therapeutic area
Immunology
Rare disease
No
- Definition
- The most common clinical variant of multiple sclerosis, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see optic neuritis), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914)
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Relapsing-remitting multiple sclerosis
- Alternative names
- relapsing-remitting multiple sclerosis
- Therapeutic area
- Immunology
- Disease mechanisms
- Developmental
- Severity
- Moderate
- Immunology
- Neurology
- MONDO ID
- MONDO:0005314
- Parent condition
- MONDO:0005301
Related records
Broader conditions (17)
- Autoimmune disease
- Autoimmune disorder of central nervous system
- Autoimmune disorder of the nervous system
- Brain disorder
- Central nervous system disorder
- CNS demyelinating autoimmune disease
- Demyelinating disease
- Demyelinating disease of central nervous system
- Disease
- Disease by body system or component
- Disease by developmental or physiological process
- Disorder of development or morphogenesis
- Human disease
- Immune system disorder
- Multiple sclerosis
- Nervous system disorder
- Neurodegenerative disease
Trials (611)
- "HB-adMSCs for the Treatment of Patients With Multiple Sclerosis"
- "Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS
- 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
- A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720
- A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients
- A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS
- A Canadian Study Assessing the Utility of the Treatment Optimization Recommendations in Multiple Sclerosis
- A Canadian Study of Persistence on Ofatumumab Using Patient Support Program Data
- A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)
- A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
- A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
- A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties
- A Multicenter Clinical Trial Evaluating the Efficacy and Safety of Taurine as an Adjunctive Therapy in Multiple Sclerosis
- A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation
- A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly
- A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
- A Observational, Prospective Study to Assess the Impact of Fatigue in the Quality of Life of Patients With Multiple Sclerosis in Argentina
- A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303
- A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis
- A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis
Approved drugs (12)
- Daclizumab
- Dimethyl fumarate
- Diroximel fumarate
- Fingolimod hydrochloride
- Natalizumab
- Ocrelizumab
- Ofatumumab
- Ozanimod hydrochloride
- Ponesimod
- Siponimod fumaric acid
- Teriflunomide
- Ublituximab
Drugs in development (93)
- Abatacept Phase 2
- Albumin human Phase 2
- Alemtuzumab Phase 3
- Amiselimod hydrochloride Phase 2
- Atorvastatin Phase 2
- Bazedoxifene acetate Phase 2
- Boswellic acid Phase 2
- Butylated hydroxytoluene Phase 2
- Caffeine Phase 3
- Carmustine Phase 2
- Cholecalciferol Phase 3
- Cladribine Phase 3
- Clemastine Phase 2
- Clemastine fumarate Phase 1
- Corticotropin Phase 3
- Cyclophosphamide Phase 3
- Cytarabine Phase 2
- D-aspartate Phase 2
- Dalfampridine Phase 3
- Dexamethasone sodium phosphate Phase 1
Other linked drugs (3)
- Modafinil
- Omega-3 fatty acids
- Tegomil fumarate